Solution NMR Investigation of the CD95/FADD Homotypic Death Domain Complex Suggests Lack of Engagement of the CD95 C Terminus

Structure

Volumn 18, Issue 10, 2010, Pages 1378-1390

  Esposito, Diego ^a   Sankar, Andrew ^a   Morgner, Nina ^b   Robinson, Carol V ^b   Rittinger, Katrin ^a   Driscoll, Paul C ^a  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; ISOLEUCINE; LEUCINE; VALINE;

ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CRYSTAL STRUCTURE; GEL PERMEATION CHROMATOGRAPHY; GENE MUTATION; GENE SEQUENCE; LIGHT SCATTERING; MASS SPECTROMETRY; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PH; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION;

AMINO ACID SEQUENCE; ANTIGENS, CD95; CARBON ISOTOPES; CRYSTALLOGRAPHY, X-RAY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; HUMANS; HYDROGEN-ION CONCENTRATION; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MULTIPROTEIN COMPLEXES; MUTATION; NITROGEN ISOTOPES; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; SEQUENCE HOMOLOGY, AMINO ACID; SOLUTIONS;

EID: 77957794023     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.str.2010.08.006     Document Type: Article

References (70)

1. Algeciras-Schimnich A., Shen L., Barnhart B.C., Murmann A.E., Burkhardt J.K., Peter M.E. Molecular ordering of the initial signaling events of CD95. Mol. Cell. Biol. 2002, 22:207-220.
2. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat. Rev. Drug Discov. 2008, 7:1001-1012.
3. Ashkenazi A., Dixit V.M. Death receptors: Signaling and modulation. Science 1998, 281:1305-1308.
4. Bang S., Jeong E.J., Kim I.K., Jung Y.K., Kim K.S. Fas- and tumor necrosis factor-mediated apoptosis uses the same binding surface of FADD to trigger signal transduction. A typical model for convergent signal transduction. J. Biol. Chem. 2000, 275:36217-36222.
5. Beneteau M., Daburon S., Moreau J.F., Taupin J.L., Legembre P. Dominant-negative Fas mutation is reversed by down-expression of c-FLIP. Cancer Res. 2007, 67:108-115.
6. Berglund H., Olerenshaw D., Sankar A., Federwisch M., McDonald N.Q., Driscoll P.C. The three-dimensional solution structure and dynamic properties of the human FADD death domain. J. Mol. Biol. 2000, 302:171-188.
7. Bidere N., Su H.C., Lenardo M.J. Genetic disorders of programmed cell death in the immune system. Annu. Rev. Immunol. 2006, 24:321-352.
8. Bodmer J.L., Holler N., Reynard S., Vinciguerra P., Schneider P., Juo P., Blenis J., Tschopp J. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat. Cell Biol. 2000, 2:241-243.
9. Boldin M.P., Varfolomeev E.E., Pancer Z., Mett I.L., Camonis J.H., Wallach D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J. Biol. Chem. 1995, 270:7795-7798.
10. Chaigne-Delalande B., Mahfouf W., Daburon S., Moreau J.F., Legembre P. CD95 engagement mediates actin-independent and -dependent apoptotic signals. Cell Death Differ. 2009, 16:1654-1664.
11. Chernushevich I.V., Thomson B.A. Collisional cooling of large ions in electrospray mass spectrometry. Anal. Chem. 2004, 76:1754-1760.
12. Chinnaiyan A.M., Orourke K., Tewari M., Dixit V.M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995, 81:505-512.
13. Delaglio F., Grzesiek S., Vuister G.W., Zhu G., Pfeifer J., Bax A. NMRPIPE-a multidimensional spectral processing system based on Unix pipes. J. Biomol. NMR 1995, 6:277-293.
14. Feig C., Tchikov V., Schutze S., Peter M.E. Palmitoylation of CD95 facilitates formation of SDS-stable receptor aggregates that initiate apoptosis signaling. EMBO J. 2007, 26:221-231.
15. Ferguson B.J., Esposito D., Jovanovic J., Sankar A., Driscoll P.C., Mehmet H. Biophysical and cell-based evidence for differential interactions between the death domains of CD95/Fas and FADD. Cell Death Differ. 2007, 14:1717-1719.
16. Goto N.K., Gardner K.H., Mueller G.A., Willis R.C., Kay L.E. A robust and cost-effective method for the production of Val, Leu, Ile (delta 1) methyl-protonated N-15-, C-13-, H-2-labeled proteins. J. Biomol. NMR 1999, 13:369-374.
17. Grzesiek S., Bax A. The importance of not saturating H2O in protein NMR. Application to sensitivity enhancement and NOE measurements. J. Am. Chem. Soc. 1993, 115:12593-12594.
18. Hernandez H., Robinson C.V. Determining the stoichiometry and interactions of macromolecular assemblies from mass spectrometry. Nat. Protoc. 2007, 2:715-726.
19. Hernandez H., Makarova O.V., Makarov E.M., Morgner N., Muto Y., Krummel D.P., Robinson C.V. Isoforms of U1-70k control subunit dynamics in the human spliceosomal U1 snRNP. PLoS ONE 2009, 4:e7202.
20. Hill J.M., Morisawa G., Kim T., Huang T., Wei Y., Wei Y.F., Werner M.H. Identification of an expanded binding surface on the FADD death domain responsible for interaction with CD95/Fas. J. Biol. Chem. 2004, 279:1474-1481.
21. Holler N., Tardivel A., Kovacsovics-Bankowski M., Hertig S., Gaide O., Martinon F., Tinel A., Deperthes D., Calderara S., Schulthess T., et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol. Cell. Biol. 2003, 23:1428-1440.
22. Huang B., Eberstadt M., Olejniczak E.T., Meadows R.P., Fesik S.W. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Nature 1996, 384:638-641.
23. Huang D.C.S., Hahne M., Schroeter M., Frei K., Fontana A., Villunger A., Newton K., Tschopp J., Strasser A. Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L). Proc. Natl. Acad. Sci. USA 1999, 96:14871-14876.
24. Hughes M.A., Harper N., Butterworth M., Cain K., Cohen G.M., MacFarlane M. Reconstitution of the death-inducing signaling complex reveals a substrate switch that determines CD95-mediated death or survival. Mol. Cell 2009, 35:265-279.
25. Huth J.R., Bewley C.A., Jackson B.M., Hinnebusch A.G., Clore G.M., Gronenborn A.M. Design of an expression system for detecting folded protein domains and mapping macromolecular interactions by NMR. Protein Sci. 1997, 6:2359-2364.
26. Imtiyaz H.Z., Zhang Y.H., Zhang J.K. Structural requirements for signal-induced target binding of FADD determined by functional reconstitution of FADD deficiency. J. Biol. Chem. 2005, 280:31360-31367.
27. Ivins F.J., Montgomery M.G., Smith S.J.M., Morris-Davies A.C., Taylor I.A., Rittinger K. NEMO oligomerization and its ubiquitin-binding properties. Biochem. J. 2009, 421:243-251.
28. Jeong E.J., Bang S., Lee T.H., Park Y.I., Sim W.S., Kim K.S. The solution structure of FADD death domain - Structural basis of death domain interactions of Fas and FADD. J. Biol. Chem. 1999, 274:16337-16342.
29. Kay L.E., Torchia D.A., Bax A. Backbone dynamics of proteins as studied by N-15 inverse detected heteronuclear NMR-spectroscopy-application to staphylococcal nuclease. Biochemistry 1989, 28:8972-8979.
30. Kischkel F.C., Hellbardt S., Behrmann I., Germer M., Pawlita M., Krammer P.H., Peter M.E. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (Dros. Inf. Serv.C) with the receptor. EMBO J. 1995, 14:5579-5588.
31. Kischkel F.C., Lawrence D.A., Chuntharapai A., Schow P., Kim K.J., Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000, 12:611-620.
32. Krammer P.H. CD95's deadly mission in the immune system. Nature 2000, 407:789-795.
33. Krueger A., Fas S.C., Baumann S., Krammer P.H. The role of CD95 in the regulation of peripheral T-cell apoptosis. Immunol. Rev. 2003, 193:58-69.
34. Lee K.H., Feig C., Tchikov V., Schickel R., Hallas C., Schutze S., Peter M.E., Chan A.C. The role of receptor internalization in CD95 signaling. EMBO J. 2006, 25:1009-1023.
35. Legembre P., Beneteau M., Daburon S., Moreau J.F., Taupin J.L. Cutting edge: SDS-stable Fas microaggregates: an early event of Fas activation occurring with agonistic anti-Fas antibody but not with Fas ligand. J. Immunol. 2003, 171:5659-5662.
36. Lin S.C., Lo Y.C., Wu H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature 2010, 465:885-890.
37. Martin D.A., Zheng L., Siegel R.M., Huang B., Fisher G.H., Wang J., Jackson C.E., Puck J.M., Dale J., Straus S.E., et al. Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia. Proc. Natl. Acad. Sci. USA 1999, 96:4552-4557.
38. McAlister M.S., Mott H.R., van der Merwe P.A., Campbell I.D., Davis S.J., Driscoll P.C. NMR analysis of interacting soluble forms of the cell-cell recognition molecules CD2 and CD48. Biochemistry 1996, 35:5982-5991.
39. Medema J.P., Scaffidi C., Kischkel F.C., Shevchenko A., Mann M., Krammer P.H., Peter M.E. FLICE is activated by association with the CD95 death-inducing signaling complex (Dros. Inf. Serv.C). EMBO J. 1997, 16:2794-2804.
40. Muppidi J.R., Lobito A.A., Ramaswamy M., Yang J.K., Wang L., Wu H., Siegel R.M. Homotypic FADD interactions through a conserved RXDLL motif are required for death receptor-induced apoptosis. Cell Death Differ. 2006, 13:1641-1650.
41. Nagata S. Apoptosis by death factor. Cell 1997, 88:355-365.
42. Natan E., Hirschberg D., Morgner N., Robinson C.V., Fersht A.R. Ultraslow oligomerization equilibria of p53 and its implications. Proc. Natl. Acad. Sci. USA 2009, 106:14327-14332.
43. Newton K., Harris A.W., Bath M.L., Smith K.G., Strasser A. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J. 1998, 17:706-718.
44. Newton K., Kurts C., Harris A.W., Strasser A. Effects of a dominant interfering mutant of FADD on signal transduction in activated T cells. Curr. Biol. 2001, 11:273-276.
45. Ollerenshaw J.E., Tugarinov V., Kay L.E. Methyl TROSY: explanation and experimental verification. Magn. Reson. Chem. 2003, 41:843-852.
46. O'Reilly L.A., Tai L., Lee L., Kruse E.A., Grabow S., Fairlie W.D., Haynes N.M., Tarlinton D.M., Zhang J.G., Belz G.T., et al. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 2009, 461:659-663.
47. Palmer A.G. NMR characterization of the dynamics of biomacromolecules. Chem. Rev. 2004, 104:3623-3640.
48. Papoff G., Hausler P., Eramo A., Pagano M.G., Di Leve G., Signore A., Ruberti G. Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor. J. Biol. Chem. 1999, 274:38241-38250.
49. Park H.H., Lo Y.C., Lin S.C., Wang L., Yang J.K., Wu H. The death domain superfamily in intracellular signaling of apoptosis and inflammation. Annu. Rev. Immunol. 2007, 25:561-586.
50. Park H.H., Logette E., Raunser S., Cuenin S., Walz T., Tschopp J., Wu H. Death domain assembly mechanism revealed by crystal structure of the oligomeric PIDDosome core complex. Cell 2007, 128:533-546.
51. Peter M.E., Budd R.C., Desbarats J., Hedrick S.M., Hueber A.O., Newell M.K., Owen L.B., Tschopp J., Wajant H., Wallach D., et al. The CD95 receptor: apoptosis revisited. Cell 2007, 129:447-450.
52. Religa T.L., Sprangers R., Kay L.E. Dynamic regulation of archaeal proteasome gate opening as studied by TROSY NMR. Science 2010, 328:98-102.
53. Roy A., Hong J.H., Lee J.H., Lee Y.T., Lee B.J., Kim K.S. In vitro activation of procaspase-8 by forming the cytoplasmic component of the death-inducing signaling complex (DISC). Mol. Cells 2008, 26:165-170.
54. Ruschak A.M., Kay L.E. Methyl groups as probes of supra-molecular structure, dynamics and function. J. Biomol. NMR 2010, 46:75-87.
55. Sandu C., Morisawa G., Wegorzewska I., Huang T., Arechiga A.F., Hill J.M., Kim T., Walsh C.M., Werner M.H. FADD self-association is required for stable interaction with an activated death receptor. Cell Death Differ. 2006, 13:2052-2061.
56. Schneider P., Holler N., Bodmer J.L., Hahne M., Frei K., Fontana A., Tschopp J. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 1998, 187:1205-1213.
57. Scott F.L., Stec B., Pop C., Dobaczewska M.K., Lee J.J., Monosov E., Robinson H., Salvesen G.S., Schwarzenbacher R., Riedl S.J. The Fas-FADD death domain complex structure unravels signalling by receptor clustering. Nature 2009, 457:1019-1022.
58. Siegel R.M., Frederiksen J.K., Zacharias D.A., Chan F.K.M., Johnson M., Lynch D., Tsien R.Y., Lenardo M.J. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000, 288:2354-2357.
59. Siegel R.M., Muppidi J.R., Sarker M., Lobito A., Jen M., Martin D., Straus S.E., Lenardo M.J. SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane. J. Cell Biol. 2004, 167:735-744.
60. Sobott F., Hernandez H., McCammon M.G., Tito M.A., Robinson C.V. A tandem mass spectrometer for improved transmission and analysis of large macromolecular assemblies. Anal. Chem. 2002, 74:1402-1407.
61. Sprick M.R., Rieser E., Stahl H., Grosse-Wilde A., Weigand M.A., Walczak H. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J. 2002, 21:4520-4530.
62. Strasser A., Jost P.J., Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 2009, 30:180-192.
63. Thorburn A. Death receptor-induced cell killing. Cell. Signal. 2004, 16:139-144.
64. Tugarinov V., Hwang P.M., Ollerenshaw J.E., Kay L.E. Cross-correlated relaxation enhanced H-1-C-13 NMR spectroscopy of methyl groups in very high molecular weight proteins and protein complexes. J. Am. Chem. Soc. 2003, 125:10420-10428.
65. Vaishnaw A.K., Orlinick J.R., Chu J.L., Krammer P.H., Chao M.V., Elkon K.B. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. J. Clin. Invest. 1999, 103:355-363.
66. Velyvis A., Yang Y.R., Schachman H.K., Kay L.E. A solution NMR study showing that active site ligands and nucleotides directly perturb the allosteric equilibrium in aspartate transcarbamoylase. Proc. Natl. Acad. Sci. USA 2007, 104:8815-8820.
67. Vranken W.F., Boucher W., Stevens T.J., Fogh R.H., Pajon A., Llinas P., Ulrich E.L., Markley J.L., Ionides J., Laue E.D. The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins 2005, 59:687-696.
68. Wilson N.S., Dixit V., Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat. Immunol. 2009, 10:348-355.
69. Yang J.K., Wang L.W., Zheng L.X., Wan F.Y., Ahmed M., Lenardo M.J., Wu H. Crystal structure of MC159 reveals molecular mechanism of DISC assembly and FLIP inhibition. Mol. Cell 2005, 20:939-949.
70. Zhou P., Lugovskoy A.A., Wagner G. A solubility-enhancement tag (SET) for NMR studies of poorly behaving proteins. J. Biomol. NMR 2001, 20:11-14.